{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/724-US10,975,364(Active) re (Done on website already).pdf"}, "page_content": "ses to include all of the eleven endogenous sites ( 6 canonical\n\nR654A mutations , i.e. SaCas9 - HF , had a significantly lower\n\nand 5 non - canonical PAMs ) previously subjected to\n\nnumber of off - target sites compared to the modified protein\n\nGUIDE - seq . A quadruple mutant , i.e. a modified protein\n\ncontaining four amino acid substitutions referred to as\n\nharboring R245A , N419A and R654A mutations , i.e. with\n\nSaCas9 - HF ( with the following four amino acid mutations : 65 out a mutation at the N413 position , showing the advanta\n\nR245A , N413A , N419A , and R654A ) , was generated to test\n\ngeous effect of the mutation at the N413 position in improv\n\nthe combined effectiveness of four mutations . The R245A\n\ning specificity of the SaCas9 protein .\n\nUS 10,975,364 B2\n\n12\n\n11\n\nNNARRT PAM (EMX1_1) for which about 20% the cleav- age efficiency of canonical PAM in an EGFR disruption assay was achieved but which has never been tested on a human endogenous target. These targets are also associated with a substantial number of off-target sites in the human genome and well suited for downstream evaluation of tar- geting specificity.\n\nmodified protein was also evaluated in view of data showing consistently high on-target cleavage efficiency.\n\nAs seen in FIG. 3B, FIG. 3C and FIG. 3F, among the six canonical PAM sites, FANCF_13 showed nine off-target sites by WT-SaCas9 and no detectable off-target sites by SaCas9-HF, illustrating the marked improved specificity of SaCas9-HF in comparison to WT-SaCas9 and improved specificity over the R245A modified protein.", "type": "Document"}}